This study identifies TNFAIP3 as a key molecular target linking chronic obstructive pulmonary disease (COPD) and insomnia, and proposes berbamine as a potential therapeutic drug, filling the gap in understanding shared mechanisms and dual-treatment strategies for this comorbidity. The gene discussed is TNFAIP3; the disease is insomnia.